John Hollon
Internal Medicine · Wilmington, OHNPI 1124092846
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,401 and has fallen 97.9% since, to $30 in 2023.
Across 250 payments — averaging $13.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$666
- Novo Nordisk$569
- AstraZeneca$225
- Boehringer Ingelheim$217
- AbbVie$196
- Amarin Pharma, Inc.$173
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,448100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 51 | $666 |
| Novo Nordisk | 53 | $569 |
| AstraZeneca | 14 | $225 |
| Boehringer Ingelheim | 12 | $217 |
| AbbVie(2 entities) | 16 | $196 |
| Amarin Pharma, Inc. | 11 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $156 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $125 |
| Merck | 8 | $119 |
| Pfizer | 7 | $117 |
| Amgen(2 entities) | 8 | $110 |
| Astellas Pharma US Inc | 6 | $93 |
| Johnson & Johnson | 5 | $77 |
| Biohaven Pharmaceuticals, Inc. | 5 | $77 |
| Bayer | 5 | $74 |
| Acerus Pharmaceuticals Corporation | 4 | $64 |
| GSK | 4 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Boston Scientific | 1 | $37 |
| Renalytix AI, Inc. | 1 | $23 |
| Pulmonx Corporation | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Medtronic | 1 | $14 |
| Abbott | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $6 |
How this compares
$3,448 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 65 | $60,150 |
| OzempicSemaglutide | 43 | $54,741 |
| EliquisApixaban | 50 | $53,727 |
| TrulicityDulaglutide | 26 | $50,591 |
| RybelsusSemaglutide | 30 | $41,213 |
| XareltoRivaroxaban | 29 | $26,756 |
| MounjaroTirzepatide | 25 | $24,428 |
| FarxigaDapagliflozin Propanediol | 15 | $19,841 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $13,366 |
| JardianceEmpagliflozin | 11 | $9,590 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $9,287 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 29 | $8,565 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $8,358 |
| InvokanaCanagliflozin | 11 | $7,882 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 35 | $7,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $569 | $95,95473 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $666 | $75,01951 claims |
| PfizerEliquis, Abrysvo, Premarin | $117 | $64,71191 claims |
| MerckJanuvia | $119 | $60,15065 claims |
| Johnson & JohnsonXarelto, Invokana | $77 | $34,63840 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $225 | $31,50250 claims |
| GSKAnoro Ellipta, Shingrix, Incruse Ellipta | $58 | $19,68659 claims |
| Boehringer IngelheimJardiance | $217 | $9,59011 claims |
| AbbVieSynthroid | $196 | $1,54544 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Wilmington
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
- Vincent MartinCincinnati$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.